Dechra Pharmaceuticals PLC (LSE:DPH) - Share price


Stock Report

Dechra Pharmaceuticals PLC DPH

Last Price
GBX4,978.00

Day Change
0.00|0.00%

As of 08/12/2021
16:31:49 GMT | GBX
Minimum 15 Minutes Delay.

Last Close4,978.00p
Day Range4,966.00 - 5,075.00
Mkt Cap5.39Bil
52-Wk Range3,132.00 - 5,525.00
Yield %0.83
ISINGB0009633180
Volume150,936
P/E95.24
P/S0.09
P/CF0.61

Share Price

Total Returns 07/12/2021

 Chg (%)  
More ...
Dechra Pharmaceuticals PLC1.06 
FTSE 100 TR GBP0.79
 
Financials
201920202021
More ...
Income Statement
Turnover481.80515.10608.00
Operating Profit45.5058.7087.00
Net Profit30.9033.9055.50
Reported EPS30.0732.7651.03
Balance Sheet
Current Assets291.50448.90392.20
Non Current Assets750.00788.70821.90
Total Assets1,041.501,237.601,214.10
Current Liabilities118.10137.30155.80
Total Liabilities532.40600.10581.20
Total Equity509.10637.50632.90
Cash Flow
Operating Cash Flow99.10119.30133.00
Net Change in Cash-0.20143.80-102.10

Regulatory News

DateAuthor Headline
26/07/2019James Gard Vodafone to Spin Off Towers Business
Shares in FTSE 100 telecoms firm surge as it unveils ambitious plans to create a separate company for its European towers and masts infrastructure
25/04/2019David Brenchley The Problem With Buy and Hold
Funds that buy stocks and hold them forever, like Fundsmith or Lindsell Train, should focus more on valuation, according to Artemis's Simon Edelsten
11/04/2019David Brenchley Mid-Cap Stocks UK Fund Managers Are Buying
Retail investors are beginning to re-enter the UK stock market at the mid-cap level and fund managers are equally positive on FTSE 250 stocks. Here are a handful of favoured names
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
05/10/2021Exercise of OptionMr. Paul Sandland2,166.003,00064,980.00
05/10/2021Exercise of OptionMr. Paul Sandland2,506.0055013,783.00
05/10/2021Exercise of OptionMr. Paul Sandland2,506.002,45061,397.00
05/10/2021Sale of OptionMr. Paul Sandland4,828.502,130102,847.00

Company Profile

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Sector

Drug Manufacturers - General

Index

FTSE 250 , FTSE 350 , FTSE All Share

Next Event 21/02/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)98.86
Div Yld (E)0.80
PEG (E)0.00
ROCE7.92
Op Mrgn0.14
EPS Grwth0.33
Dividends
PreviousLatest
More ...
Record Date05/03/2129/10/21
Ex-Div04/03/2128/10/21
Paid07/04/2119/11/21
Amnt11.1129.39
Directors
More ...
Executive Director, Chief ExecutiveMr. Ian David Page
Non-Executive Director, ChairmanMr. William Anthony Rice
Non-Executive Director, Senior Independent Non-Executive DirectorMs. Ishbel Jean Stewart Macpherson
Non-Executive DirectorMs. Alison Elizabeth Platt
Executive Director, Chief Financial OfficerMr. Paul Sandland
Executive Director, Managing Director, Dechra Veterinary Products EUMr. Anthony Griffin
Non-Executive DirectorDr. Lawson Macartney
Non-Executive DirectorMs. Lisa Bright
Non-Executive DirectorMs. Denise Goode
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.